Research progress of PD-1/PD-L1 in prostate cancer immunotherapy
Prostate cancer is the second most common cancer in men and the fifth leading cause of cancer deaths in men.Al-though there is an initial response to traditional treatments which include radical prostatectomy,chemotherapy,androgen depriva-tion therapy,and so on,some patients eventually progress to castration-resistant prostate cancer.The human immune system can perform a monitoring function to kill tumor cells promptly,however,tumor cells also express PD-L1 as they evolve,which binds to PD-1 on T cells and can inhibit T cell function,ultimately inducing immune evasion.The in-depth study of PD-1/PD-L1 in the mechanism of immune evasion in prostate cancer may provide new therapeutic strategies for the future application of PD-1/PD-L1-based immunotherapy in prostate cancer treatment.In this paper,we will review the latest research progress of PD-1/PD-L1 in prostate cancer immunotherapy.
国家科技期刊平台
NSTL
万方数据
